ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Biotechnology

Healthcare
$3.69 -3.51%

-$0.35 today

Market cap
$370.95M
Beta
0.83
P/E (TTM)
-4.8
EPS (TTM)
-$1.99
52W Low $6.66High $18.90

Volume 1.70M

Average 1.67M

Balance Sheet

Inspect the capital base behind the business.

Assets

$327.65M

FY 2025 · Annual

-6.7% YoY

Liabilities

$213.39M

FY 2025 · Annual

+126.2% YoY

Equity

$114.26M

FY 2025 · Annual

-55.5% YoY

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents60.06M210.52M70.97M50.82M41.32M
Short-term Investments063.86M157.39M263.21M203.67M
Net Receivables1K0795K9.16M26.35M
Inventory0005.21M8.37M
Other Current Assets01.01M01.23M5.19M
Total Current Assets60.73M277.7M231.56M334.3M284.9M
Property, Plant & Equipment (Net)693K774K824K1.07M2.47M
Goodwill00000
Intangible Assets0007.69M14.45M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets23K2.96M801K8.11M25.84M
Total Non-current Assets716K3.74M1.63M16.86M42.76M
Total Assets61.45M281.44M233.19M351.15M327.65M
Account Payables1.79M1.66M759K9.87M5.73M
Short-term Debt3.48M0237K00
Tax Payables004K00
Deferred Revenue1.46M00557K609K
Other Current Liabilities660K1.46M1.08M2.29M588K
Total Current Liabilities8.19M5.44M2.39M23.44M39.15M
Long-term Debt4.93M00096.37M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)3M001.53M1.13M
Other Non-current Liabilities76.12M2.85M069.38M76.75M
Total Non-current Liabilities84.53M3.11M37K70.92M174.25M
Total Liabilities92.72M8.55M2.43M94.36M213.39M
Common Stock3K9K10K10K10K
Retained Earnings(42.26M)(76.94M)(131.3M)(123.31M)(294.6M)
Accumulated OCI0407K49K220K125K
Other Stockholders Equity01000
Minority Interest00000
Total Equity(31.27M)272.89M230.76M256.8M114.26M
Total Debt9.03M481K274K42K96.37M
Net Debt(51.03M)(210.04M)(70.7M)(50.78M)55.06M

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$24.3M
Short-term Investments$176.6M
Receivables$29.5M
Inventory$8.8M
Other Current$6.0M
Total Current Assets$245.2M
PP&E (Net)$2.3M
Intangible Assets$14.2M
Other Non-current$25.9M
Total Non-current Assets$42.3M
Total Assets$287.6M

Analysis

Selected assets total $287.6M for Latest. The largest visible component is Short-term Investments at $176.6M, about 61.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
3Initial statement of beneficial ownershipNov 4, 2026
4Statement of changes in beneficial ownershipNov 4, 2026
4Statement of changes in beneficial ownershipOct 5, 2026

How much cash does SPRY have?

ARS Pharmaceuticals, Inc. (SPRY) reported $41.32M in cash and equivalents in fiscal 2025.

How much debt does SPRY carry?

ARS Pharmaceuticals, Inc. (SPRY) reported $96.37M of total debt, with net debt of $55.06M.